Literature DB >> 9930722

Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells.

S Ruan1, B K Raj, K O Lloyd.   

Abstract

Most human neuroblastoma tumors are characterized by the high expression of GD2 (or GD2 and/or GM2) gangliosides, whereas melanomas characteristically express GD3 ganglioside. The molecular basis for these patterns was investigated by examining the relationship between ganglioside levels, glycosyltransferase (GM2/GD2 synthase and GD3 synthase) activity, and corresponding mRNA levels in a panel of human neuroblastoma and melanoma cell lines. In general, the ganglioside patterns could be explained by the levels of the transferases and their mRNA, indicating control at the level of transcription. A key role was noted for GD3 synthase. Notably, it was found that neuroblastoma cell lines with high GD2 ganglioside levels had low levels of GD3, its synthase, and mRNA for the enzyme even though this step provides the substrate for GD2 synthesis. The key role for GD3 synthase was also examined by stably transfecting GD3 synthase cDNA into a neuroblastoma cell line (SH-SY5Y) not expressing GD3 and GD2. The resulting cell line had high levels of GD2 ganglioside and altered morphology and growth characteristics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930722     DOI: 10.1046/j.1471-4159.1999.0720514.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

Review 1.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  Triptolide downregulates human GD3 synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells.

Authors:  Haw-Young Kwon; Seok-Jo Kim; Cheorl-Ho Kim; Sung-Wook Son; Kyoung-Sook Kim; Jai-Heon Lee; Su-Il Do; Young-Choon Lee
Journal:  Exp Mol Med       Date:  2010-12-31       Impact factor: 8.718

3.  Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.

Authors:  R G Uzzo; P Rayman; V Kolenko; P E Clark; M K Cathcart; T Bloom; A C Novick; R M Bukowski; T Hamilton; J H Finke
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 4.  Sphingolipids in neuroblastoma: their role in drug resistance mechanisms.

Authors:  Hannie Sietsma; Anne Jan Dijkhuis; Willem Kamps; Jan Willem Kok
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 5.  Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin.

Authors:  Guido Kohla; Eggert Stockfleth; Roland Schauer
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

6.  Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction.

Authors:  Soumika Biswas; Kaushik Biswas; Amy Richmond; Jennifer Ko; Sankar Ghosh; Matthew Simmons; Patricia Rayman; Brian Rini; Inderbir Gill; Charles S Tannenbaum; James H Finke
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

7.  An antibody to de-N-acetyl sialic acid containing-polysialic acid identifies an intracellular antigen and induces apoptosis in human cancer cell lines.

Authors:  Lindsay M Steirer; Gregory R Moe
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

8.  Lectin binding profiles of SSEA-4 enriched, pluripotent human embryonic stem cell surfaces.

Authors:  Alison Venable; Maisam Mitalipova; Ian Lyons; Karen Jones; Soojung Shin; Michael Pierce; Steven Stice
Journal:  BMC Dev Biol       Date:  2005-07-21       Impact factor: 1.978

Review 9.  Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy.

Authors:  Sophie Groux-Degroote; Philippe Delannoy
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles.

Authors:  Cristina Tringali; Ilaria Silvestri; Francesca Testa; Paola Baldassari; Luigi Anastasia; Roberta Mortarini; Andrea Anichini; Alejandro López-Requena; Guido Tettamanti; Bruno Venerando
Journal:  BMC Cancer       Date:  2014-08-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.